Raymond Khoudary, MD
Allergy & Immunology · Plains, PANPI 1396727236
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $12,800 of the $13,271 with a category attached, or 96.5%. GSK accounts for 96.5% of it on its own, with 10 other manufacturers making up the rest. Reporting peaked in 2023 at $3,915 and has fallen 97.0% since, to $116 in 2025.
Across 22 payments — averaging $603.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$13K
- Novartis$122
- Sanofi-aventis U.S. LLC$79
- Grifols USA, LLC$78
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$73
- AstraZeneca$25
- plus $88 from 5 others
What the payments were for
- Speaking & faculty fees$12,80096%
- Food & beverage$3803%
- Education$911%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 11 | $12,805 |
| Novartis | 1 | $122 |
| Sanofi-aventis U.S. LLC | 1 | $79 |
| Grifols USA, LLC | 1 | $78 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $73 |
| AstraZeneca | 2 | $25 |
| Paratek Pharmaceuticals, Inc. | 1 | $20 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $19 |
| Watermark Medical, Inc. | 1 | $17 |
| Optinose US, Inc. | 1 | $17 |
| Sanofi | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRELEGY ELLIPTA$8,900
- XOLAIR$122
How this compares
$13,271 in reported general payments places this provider in the 80th percentile of 175 allergy & immunology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 121 | $87,044 |
| Breo ElliptaFluticasone/Vilanterol | 137 | $75,457 |
| Dupixent PenDupilumab | 14 | $61,261 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 108 | $20,548 |
| SymbicortBudesonide/Formoterol Fumarate | 42 | $14,978 |
| Arnuity ElliptaFluticasone Furoate | 37 | $13,300 |
| Advair HfaFluticasone Propion/Salmeterol | 16 | $10,516 |
| Fluticasone Propionate HfaFluticasone Propionate | 19 | $4,789 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 18 | $3,759 |
| Wixela InhubFluticasone Propion/Salmeterol | 23 | $3,642 |
| Montelukast Sodium | 231 | $3,070 |
| Mometasone Furoate | 42 | $2,927 |
| Fluticasone Propionate | 124 | $2,612 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 94 | $2,338 |
| Epinephrine | 14 | $2,132 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta | $12,805 | $175,801295 claims |
| AstraZenecaSymbicort | $25 | $14,97842 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 175 allergy & immunology providers in Pennsylvania.
Other allergy & immunology in Plains
- Drew WeissmanPhiladelphia$12.8M
- Eric SchenkelBethlehem$845K
- Sergei BelenkyPittsburgh$775K
- Timothy CraigHershey$564K
- Sandra GawchikUpland$390K
- Anthony RooklinGlen Mills$319K
- Corinna BowserNarberth$229K
- Shailen ShahCollegeville$183K
- Michael PremattaHavertown$168K
- Donald HarperMechanicsburg$142K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.